Thymic carcinoma natural history, complications and prognosis: Difference between revisions
Jump to navigation
Jump to search
| Line 17: | Line 17: | ||
==Prognosis== | ==Prognosis== | ||
The most important factor for prognosis is the stage and grade of the thymic carcinoma. The 5-year and 10-year overall survival rates in patients with thymic carcinoma are 38% and 28%, respectively. <ref name="Ogawa-2002">{{Cite journal | last1 = Ogawa | first1 = K. | last2 = Toita | first2 = T. | last3 = Uno | first3 = T. | last4 = Fuwa | first4 = N. | last5 = Kakinohana | first5 = Y. | last6 = Kamata | first6 = M. | last7 = Koja | first7 = K. | last8 = Kinjo | first8 = T. | last9 = Adachi | first9 = G. | title = Treatment and prognosis of thymic carcinoma: a retrospective analysis of 40 cases. | journal = Cancer | volume = 94 | issue = 12 | pages = 3115-9 | month = Jun | year = 2002 | doi = 10.1002/cncr.10588 | PMID = 12115342 }}</ref> | *The most important factor for prognosis is the stage and grade of the thymic carcinoma. | ||
*The 5-year and 10-year overall survival rates in patients with thymic carcinoma are 38% and 28%, respectively. <ref name="Ogawa-2002">{{Cite journal | last1 = Ogawa | first1 = K. | last2 = Toita | first2 = T. | last3 = Uno | first3 = T. | last4 = Fuwa | first4 = N. | last5 = Kakinohana | first5 = Y. | last6 = Kamata | first6 = M. | last7 = Koja | first7 = K. | last8 = Kinjo | first8 = T. | last9 = Adachi | first9 = G. | title = Treatment and prognosis of thymic carcinoma: a retrospective analysis of 40 cases. | journal = Cancer | volume = 94 | issue = 12 | pages = 3115-9 | month = Jun | year = 2002 | doi = 10.1002/cncr.10588 | PMID = 12115342 }}</ref> | |||
The subtypes squamous cell carcinoma, mucoepidermoid and basaloid carcinoma have a better prognosis than other histological subtypes. For neuroendocrine carcinomas, the malignancy is intermediate between thymoma and thymic carcinoma, being the small cell and large cell carcinomas the most malignant. | *The subtypes squamous cell carcinoma, mucoepidermoid and basaloid carcinoma have a better prognosis than other histological subtypes. | ||
*For neuroendocrine carcinomas, the malignancy is intermediate between thymoma and thymic carcinoma, being the small cell and large cell carcinomas the most malignant. | |||
==References== | ==References== | ||
Revision as of 16:28, 30 December 2015
|
Thymic Carcinoma Microchapters |
|
Diagnosis |
|---|
|
Case Studies |
|
Thymic carcinoma natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Thymic carcinoma natural history, complications and prognosis |
|
FDA on Thymic carcinoma natural history, complications and prognosis |
|
CDC on Thymic carcinoma natural history, complications and prognosis |
|
Thymic carcinoma natural history, complications and prognosis in the news |
|
Blogs on Thymic carcinoma natural history, complications and prognosis |
|
Risk calculators and risk factors for Thymic carcinoma natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alejandro Lemor, M.D. [2]Parminder Dhingra, M.D. [3]
Overview
Natural History
- Thymic carcinomas are generally considered indolent tumors due to long recurrence intervals (median of 68 months).
- Overall, for patients diagnosed with a resectable thymic tumor, 16% of them will recur after radical resection, either locally with pleural or ganglionar recurrence or with distant metastases.
- The most common sites of distant recurrence are lung, liver, bone, kidney, brain and bone marrow.[1]
Complications
- There are no reported cases of complications regarding the carcinoma by itself.
- Most complications occur during surgery and biopsy.
Prognosis
- The most important factor for prognosis is the stage and grade of the thymic carcinoma.
- The 5-year and 10-year overall survival rates in patients with thymic carcinoma are 38% and 28%, respectively. [2]
- The subtypes squamous cell carcinoma, mucoepidermoid and basaloid carcinoma have a better prognosis than other histological subtypes.
- For neuroendocrine carcinomas, the malignancy is intermediate between thymoma and thymic carcinoma, being the small cell and large cell carcinomas the most malignant.
References
- ↑ "Recurrence of thymoma: clinicopathological feat... [J Surg Oncol. 2001] - PubMed - NCBI".
- ↑ Ogawa, K.; Toita, T.; Uno, T.; Fuwa, N.; Kakinohana, Y.; Kamata, M.; Koja, K.; Kinjo, T.; Adachi, G. (2002). "Treatment and prognosis of thymic carcinoma: a retrospective analysis of 40 cases". Cancer. 94 (12): 3115–9. doi:10.1002/cncr.10588. PMID 12115342. Unknown parameter
|month=ignored (help)